GlassScriptPhysician profile
Ardis A Moe
NPI 1851408876
$11,224.80
in general payments reported to CMS, 2019-2025
12 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $521 · 2021: $1,226 · 2022: $1,716 · 2023: $2,242 · 2024: $2,468 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,839 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,839.22 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,833.05 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,524.85 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $948.00 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $831.46 | 2019-2025 | |
| Janssen Biotech, INC. | $431.51 | 2019-2022 | |
| Janssen Products, LP | $198.95 | 2021-2022 | |
| Emd Serono, INC. | $198.79 | 2019-2023 | Serostim |
| Theratechnologies INC. | $195.35 | 2019-2024 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $19.24 | 2024 | Mytesi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Mylan Institutional INC. | $13.64 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ardis Moe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.